Clinical Trials and Phase II are overseen by the DSMB and Medsafe,, there can be no detrimental effect on the trial patient otherwise the trial is abandoned immediately , clinical observers also ask multitudes of questions to trial patients... I can only say if something was wrong you would have heard straight away... so from deduction things are on track,,,or better...
Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-48
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.0¢ | 33.5¢ | $2.103M | 6.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32406 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 234417 | 5 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
